Creso’s launch of cannaQIX® tea products opens up new opportunities
Creso Pharma Limited (ASX:CPH; FRA:1X8) has launched its proprietary CBD-based teas products in Switzerland with other European markets, including Germany, earmarked for near-term expansion.
Three new products have been launched under the cannaQIX® brand and include cannaQIX® tea, cannaQIX® NITE tea and cannaQIX® Immunity tea.
While the additional revenue streams generated by the launch of these products will be important for Creso Pharma, it will also assist in promoting the broader cannaQIX® brand.
Creso has a proven track record for successful product development and commercialisation, with its cannaQIX® brand of products now available in Switzerland and several European countries.
The three new teas as illustrated below have been developed based on a new second generation innovative technology that optimises the CBD content in compliance with regulations and allows for a better taste.
Features of new products
The development of the new tea products is a groundbreaking technological achievement for Creso Pharma and provides the company with a significant competitive advantage.
Creso will now progress the use of the new technology in the manufacturing of its cannaQIX® lozenge flagship products.
Looking specifically at the three different products, cannaQIX® tea is designed to help the management of stress, supporting a better quality of life, while cannaQIX® NITE tea should be consumed at night with a view to providing a better night’s sleep.
The cannaQIX® Immunity tea provides supplements and taste to optimise well-being.
Having completed the necessary legal and regulatory due diligence, the new tea products can now be legally marketed and sold throughout Switzerland, leveraging Creso’s established distribution network comprised of over 2,100 points of sales across Switzerland where Creso’s cannaQIX® products are already being sold.
These include pharmacies, pharmacy networks, drugstores, health nutrition shops and large retail groups including leading department store chain Manor.
Creso also supplies all major wholesalers in the country including Galexis, Amedis and Voigt.
This provides the company with an established footprint, significantly de-risking the launch of each new product it brings to market.
Commenting on the launch of the new products and the scope for taking advantage of associated opportunities, commercial and development director Doctor Gian Trepp said, “We are proud to have completed the finalisation of this ground-breaking technology for our new CBD tea products, which opens a number of new and globally applicable opportunities for Creso Pharma.
"The new products and formulation provide a very tasty CBD tea that will become a key component in the future production of the cannaQIX® lozenges.
"We look forward to providing further updates on future product additions and our European expansion initiatives.”
Proposed launch of hemp tea products in Germany
Management will also look to launch its new hemp tea products in Germany following a recent decision by the German Federal Court of Justice to annul previous charges against hemp tea sellers which had temporarily delayed the scheduled rollout of the company’s hemp tea products in the September quarter of 2020.
The favourable decision has removed ambiguity over the guidelines concerning the sale of food products based on hemp flowers and leaves in Germany, leaving Creso well-positioned to actively market and sell its hemp tea products in that jurisdiction without any further regulatory approvals or hurdles to overcome.
Upon successful rollout of its new products in Switzerland and Germany, Creso will explore the opportunity to expand the distribution of its hemp tea products into other European companies, and in line with its standard practices, the group will undertake the necessary due diligence to confirm the legality of the sale of its products in each new jurisdiction as required.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.